Prostate Cancer Coverage from Every Angle

Recent News

Is Adding Palbociclib to Androgen-Deprivation Therapy of Benefit in Prostate Cancer?
Localized Intermediate-Risk Prostate Cancer: MRI-Guided Focused Ultrasound Ablation
AACR 2021: Exploratory Analysis of Molecular Signatures From TITAN Trial in Prostate Cancer
AACR 2021: Is the B7-H3 Protein an Actionable Target in Prostate Cancer?
AACR 2021: Prostate Cancer Risk, Obesity, and Diabetes
AACR 2021: Role of a Healthy Lifestyle in Offsetting Genetic Risks for Prostate Cancer
Cardiovascular Risk Factors and Prostate Cancer in U.S. Veterans
AACR 2021: Nivolumab Plus Ipilimumab in Biomarker-Selected Patients With Metastatic Prostate Cancer
Are Antiepileptic Drugs Linked to Reduced Risk of Prostate Cancer?
Urologists’ Attitudes About Active Surveillance for Low-Risk Prostate Cancer: Survey Findings
Phase III Trial Update on Ipatasertib Plus Abiraterone in Metastatic Prostate Cancer
Can White Button Mushroom Extract Slow the Growth of Prostate Cancer?
Erectile Dysfunction and Sexual Satisfaction After Robot-Assisted Radical Prostatectomy
Nivolumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer
Active Surveillance for Low-Risk Prostate Cancer: Practice Variation by Geographic Location
KEYNOTE-365 Update on Pembrolizumab Plus Chemotherapy for Metastatic Prostate Cancer
Novel Protein Inhibitor CCS1477 Under Study in Treatment-Resistant Prostate Cancer
Are Genetic Factors Potentially Driving Prostate Cancer in Black Individuals?
GU Symposium 2021: Adding Pembrolizumab to Radium-223 for Metastatic Castration-Resistant Prostate Cancer
Taking on Prostate Cancer and Myeloma: A Man Named Steele
GU Symposium 2021: Novel Tool for Predicting Metastasis After Radiotherapy for Prostate Cancer
GU Symposium 2021: Dose-Intensified Approach to Salvage Radiotherapy in Biochemically Recurrent Prostate Cancer
$3.8 Million Donation to Mount Sinai to Support Accessibility to Prostate Cancer Screening for Black Men
GU Symposium 2021: Final TITAN Trial Results in Metastatic Prostate Cancer
Delays in Radical Prostatectomy: Oncologic Outcomes in High-Risk Prostate Cancer
GU Symposium 2021: Final ACIS Results on Apalutamide-Based Therapy for Metastatic Prostate Cancer
GU Symposium 2021: Results From the Biomarker Cohort of the Phase III SPARTAN Trial
GU Symposium 2021: Does Less PSA Screening Mean More Metastatic Prostate Cancer?
Is Extended Pelvic Lymph Node Dissection Associated With Perioperative Complications?
Radical Prostatectomy Versus Radiotherapy for Localized Ductal Prostate Cancer
Germline Variations May Contribute to Population Differences in Prostate Cancer Risk
Causes of Death During Prostate Cancer Survivorship: Population-Based Analyses
Unique Immune-Oncologic Characteristics Identified in African American Men With Prostate Cancer
Steroid Switch in Metastatic Prostate Cancer: Outcomes of PSA Responders Versus Nonresponders
Use of Apalutamide in Men With Lower-Risk Prostate Cancer on Active Surveillance
Final Analysis of PROfound Trial: Olaparib in Metastatic Castration-Resistant Prostate Cancer
Enzalutamide Versus Bicalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Novel Immunotherapy Combination in Metastatic Prostate Cancer Moves on to Phase II
PSA Levels and Outcomes in High-Risk Prostate Cancer Treated With ADT and Radiotherapy
Comparison of Outcomes With Various Treatments of Localized Prostate Cancer
Is Adjuvant Radiotherapy Beneficial After Radical Prostatectomy?
Relugolix Receives FDA Approval for Advanced Prostate Cancer
IL-7 After Sipuleucel-T for Advanced Prostate Cancer
11C-Choline PET/CT and Stereotactic Ablative Radiotherapy in Prostate Cancer
Does Sequencing of ADT With Radiotherapy Impact Long-Term Outcomes in Localized Prostate Cancer?
Alternative to ADT for Prostate Cancer: Older Men May Benefit From Combination Therapy
Immunochemotherapy for Metastatic Castration-Resistant Prostate Cancer: KEYNOTE-365 Cohort B Update
First PSMA-Targeted PET Imaging Agent Approved by FDA for Men With Prostate Cancer
Adding Abiraterone Acetate Plus Prednisolone to ADT for Metastatic Prostate Cancer
ASTRO 2020: Relugolix Versus Leuprolide for Localized and Recurrent Prostate Cancers
ASTRO 2020: Long-Term Follow-up With Low–Dose-Rate Prostate Brachytherapy
Prostate Cancer Prevalence in Men With Li-Fraumeni Syndrome
ASTRO 2020: Metastasis-Free Survival as Surrogate for Overall Survival in Recurrent Prostate Cancer
Is Increased Adiposity Causally Protective for Prostate Cancer?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.